EAU 2024
Get the latest research and practical clinical applications from the 24th International European Association of Urology Meeting.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Signatera quantifies cancer and the time of any recurrence events to assist in identifying treatment options.
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
Patients who undergo RNU have comparative or better long-term outcomes than patients undergoing NSS for organ-localized UTUC.
While most STMs are benign, between 13% and 21% are malignant, and distinguishing between them remains a challenge.
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
The nomogram is used preoperatively to determine the probability of nodal tropism.
Researchers assessed recurrence rates, overall survival, and disease progression.
Previous trials have revealed that neoadjuvant chemotherapy is an effective treatment path for patients with high-grade UTUC.
Research into the potential benefits of ctDNA for patients with testicular cancer both before and after diagnosis is lacking.
Advertisement
Advertisement
